NEWS
Summary
3 June, 2019
Change of Company Name

Effective 3 June 2019, our company name has been changed from "New B Innovation Limited" to "New Beta Innovation Limited".
Please note that the company structure, the current contracts and agreements as well as the Chinese company name “新行健醫藥科技有限公司” remain unchanged.

11 January, 2019
Commencement of FiH Healthy Volunteer Study

The First-in-Human (FiH) healthy volunteer study to evaluate safety on the use of YQ23 has commenced on 11 Jan 2019. This study is mainly to assess the safety, tolerability and pharmacokinetics (PK - the amount of study drug in the blood) of ascending single dose of YQ23 in healthy male and female subjects. The clinical trial is conducted at a Phase 1 centre in UK and will enroll approximately 40 subjects.

11 July, 2016
Approval of Clinical Trial Application in HK

New Beta Innovation receives approval from the Hong Kong Department of Health (DoH) to proceed with a Phase 1 Clinical Trial (First-in-Patient) of YQ23 in patients with advanced tumors.

21 March, 2016
EMA Orphan Medicinal Product Designation

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

13 October, 2015
Approval of Clinical Trial Application in UK

New Beta Innovation receives UK Medicines and Healthcare products Regulatory Agency (MHRA) approval to proceed with a Phase 1 Clinical Trial (First-in-Human) of YQ23 in healthy volunteers.

19 November, 2014
EMA Orphan Medicinal Product Designation

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.

× We use page tagging techniques and cookies to improve the site, provide services to you, and customize your browsing experience. By continuing to browse the site you are agreeing to accept our use of cookies